Skip to main content

Legal Update

FDA Issues Guidance on Interchangeable Biosimilars

25 January 2017
Mayer Brown Legal Update

The US Food and Drug Administration recently released its long-awaited draft guidance addressing the standards for demonstrating interchangeability of biological products under the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”). The BPCIA amended the Public Health Service Act to create an abbreviated pathway for FDA licensure of biologics that are biosimilar to, or interchangeable with, a reference product. This Legal Update takes a close look at the draft guidance, which calls, among other things, for developers of biosimilars to use switching studies when they wish to demonstrate that a biosimilar product is interchangeable with a reference product and will produce the same clinical result with no greater risk.


The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.